1st line Relapsed or Metastatic mucosal, HNSCC, not NPC

Treatment

HPV(+)

Prior ICI, Injectable lesions

HPV(-)

Any PDL1

PDL1(+)

EN0073
Phase I
CUE-101
Monotherapy in
HPV+ Recurrent/
Metastatic Head
& Neck
Squamous Cell
Carcinoma
(HNSCC)

PI: Colevas
Cue Biopharma

ENT0097
A Phase II
Study of
Ipatasertib in
Combination
with
Pembrolizumab
for First Line
Treatment of
Recurrent or
Metastatic
Squamous Cell
Carcinoma
of the Head and Neck

PI: Colevas
BioNTech SE

ENT0084
Phase II
Pembrolizumab
+/- BNT113 in
HNSCC Which
is HPV+ and
Expresses
PD-L1

PI: Colevas
Gilead Sciences, Inc.

ENT0088
Phase II
Magrolimab
Combination
Therapy in
Head and Neck
Squamous Cell
Carcinoma

PI: Colevas
Gilead Sciences, Inc.

ENT0064
Phase 1b
Ad/PNP-F-
araAMP +
Co-Admin of
Fludarabine
Phosphate in
Recurrent
Local Head
& Neck Cancer

PI: Colevas
PNP
Therapeutics

ENT0088
Phase II
Magrolimab
Combination
Therapy in
Head and Neck
Squamous Cell
Carcinoma

PI: Colevas
Gilead Sciences, Inc.

ENT0097
A Phase II
Study of
Ipatasertib in
Combination
with
Pembrolizumab
for First Line
Treatment of
Recurrent or
Metastatic
Squamous Cell
Carcinoma
of the Head and Neck

PI: Colevas
National Cancer
Institute (NCI)

KEY

Pending
Open for Enrollment
Observational Study

Link
Trial Posting

Optional Path

Extension Study

Immunotherapy

Enrollment on Hold